#PHVS hashtag - Bluesky

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE

3 weeks ago

#PHVS Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

www.stocktitan.net/news/PHVS/deucrictibant-...

0 0 0 0

Pharvaris Outlines 2026 Strategic Priorities Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a

2 months ago

#PHVS Pharvaris Outlines 2026 Strategic Priorities

www.stocktitan.net/news/PHVS/pharvaris-outl...

0 0 0 0

Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks with strong volume gains, Wed Dec 3rd - #TROO #RR #QCLS #PHVS #MNTS #KITT #KALV #IRBT #HTOO #FRST #DBVT #CAPR #BCTX #ABTC #WDH #NLOP #DSX #CXM - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks Pharvaris (NASDAQ: PHVS) reported positive topline results from the RAPIDe-3 pivotal Phase 3 study of oral deucrictibant IR 20 mg for on-demand treatment of hereditary angioedema (HAE) attacks.The primary endpoint was met: median time to onset of symptom relief was 1.28 hours vs >12 hours for placebo (p<0.0001). All 11 secondary endpoints were significant, including End of Progression™ 17.47 minutes11.95 hoursDeucrictibant was well tolerated with no treatment-related serious adverse events; NDA filings are planned starting H1 2026.

3 months ago

#PHVS Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

www.stocktitan.net/news/PHVS/pharvaris-anno...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

3 months ago

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now | The Motley Fool General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund may be anticipating and the signals investors should track next.

#PHVS #DLO #XP #ALHC #CHYM #ALKT #3be2ccac-76b0-46ed-88a1-6b6105093806 #coveragefilings

Origin | Interest | Match

0 0 0 0

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update Pharvaris (Nasdaq: PHVS) reported Q3 2025 results and a business update highlighting pivotal Phase 3 programs for deucrictibant. RAPIDe-3 (on-demand HAE, 20 mg immediate-release) reached ~120 participants and topline data are expected in 4Q2025. CHAPTER-3 (prophylaxis, 40 mg extended-release) enrollment is progressing with topline data anticipated in 2H2026. Pharvaris initiated CREAATE (AAE-C1INH pivotal study) and reported Phase 2 CHAPTER-1 OLE on-treatment attack rate of 0.12. Corporate financing included a public offering with proceeds of approximately $201 million. Cash and cash equivalents were €329 million as of September 30, 2025, providing runway into H1 2027. Q3 operating metrics: R&D €29.8M, G&A €9.8M, net loss €37.1M (loss per share €0.60).

4 months ago

#PHVS Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PHVS/pharvaris-repo...

0 0 0 0

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentations Final data from participants in the open-label portion of the CHAPTER-1 study

4 months ago

#PHVS Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

www.stocktitan.net/news/PHVS/data-supportin...

0 0 0 0

Leading Indicators, Thursday August 21, 2025 – Crystal Equity Research

7 months ago

Small-cap stocks with improving money flow, Thu Aug 21st - #ZYME #TRST #SENEA #PHVS #MRCC #IMRX #HOPE #VALN #EDUC #CRON #SVV #HRTG #FFWM #CATO - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update Pharvaris (NASDAQ:PHVS) reported Q2 2025 financial results and provided significant pipeline updates for its oral bradykinin B2 receptor antagonist programs. The company anticipates topline results from RAPIDe-3, a pivotal Phase 3 study for HAE attack treatment, in Q4 2025. Enrollment continues in CHAPTER-3, another Phase 3 study for HAE attack prophylaxis, with results expected in 2H 2026.The company strengthened its financial position with €200 million in cash as of June 30, 2025, and subsequently raised $201 million through a public offering, extending its cash runway into 1H 2027. Q2 2025 financial results showed R&D expenses of €29.6 million and a net loss of €45.5 million (€0.83 per share). [ "Successful $201 million public offering extends cash runway into 1H 2027", "Multiple Phase 3 trials progressing on schedule with RAPIDe-3 results expected in Q4 2025", "Strong cash position of €200 million as of June 30, 2025", "Pipeline expansion into additional indications including AAE-C1INH" ]

7 months ago

#PHVS Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PHVS/pharvaris-repo...

0 0 0 0

Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline Biotech firm raises $175M through share offering at $20/share to advance oral treatments for hereditary angioedema. See financing details and development pipeline.

8 months ago

#PHVS Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

www.stocktitan.net/news/PHVS/pharvaris-anno...

0 0 0 0

Pharvaris Announces Proposed Public Offering of Ordinary Shares Pharvaris (NASDAQ: PHVS), a late-stage biopharmaceutical company focused on bradykinin-mediated diseases, has announced a proposed public offering of $150 million in ordinary shares. The company will also grant underwriters a 30-day option to purchase up to an additional $22.5 million in shares.The proceeds will fund research and development for late-stage clinical programs, establish a U.S. sales and marketing team, and support working capital needs. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are serving as joint book-running managers for the offering.

8 months ago

#PHVS Pharvaris Announces Proposed Public Offering of Ordinary Shares

www.stocktitan.net/news/PHVS/pharvaris-anno...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

8 months ago

Small-cap stocks with strong volume declines, Mon Jul 14th - #TANH #SXTP #SINT #MSW #ZTEK #TCRT #RYET #PHVS #MOVE #ISPO #HTOO #AIFF #CNF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 Pharvaris (Nasdaq: PHVS) has updated the timeline for topline data from its RAPIDe-3 pivotal Phase 3 study of deucrictibant immediate-release (IR) capsule for hereditary angioedema (HAE) attacks. The company now expects to announce results in Q4 2025, with plans to submit a New Drug Application (NDA) to the FDA in 1H 2026.The RAPIDe-3 study is evaluating a 20 mg single-capsule oral dose in approximately 120 participants aged 12 and older with HAE. The trial includes patients with C1 inhibitor deficiency and normal C1INH. The primary endpoint focuses on time to onset of symptom relief, with secondary endpoints including time to End of Progression, substantial symptom relief, and complete symptom resolution.

8 months ago

#PHVS Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

www.stocktitan.net/news/PHVS/pharvaris-upda...

0 0 0 0

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, will present multiple clinical trial results for deucrictibant, their oral bradykinin B2 receptor antagonist for treating hereditary angioedema (HAE), at the upcoming 2025 US HAEA National Summit in Baltimore.The presentations include six poster sessions scheduled for July 11, covering long-term safety and efficacy data from the CHAPTER-1 and RAPIDe-2 extension studies, quality of life improvements, CHAPTER-3 Phase 3 trial design, durability of response, and comparison with standard of care. All posters will be available on the company's investor relations website.

9 months ago

#PHVS Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

www.stocktitan.net/news/PHVS/pharvaris-anno...

0 0 0 0

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress Pharvaris presented comprehensive data at EAACI Congress 2025 showcasing the potential of deucrictibant, their oral bradykinin B2 receptor antagonist, for treating and preventing bradykinin-mediated angioedema attacks. Key findings from multiple studies demonstrated deucrictibant's efficacy: The CHAPTER-1 open-label extension study showed sustained attack reduction and improved quality of life, while the RAPIDe-2 extension study revealed a median time to symptom relief of 1.1 hours, with 97.8% of attacks achieving relief by 12 hours. Notably, 89.2% of attacks were resolved with a single dose. For upper airway attacks, 92.9% were effectively treated with one dose. The company also presented data on their novel kinin biomarker assay for better diagnosis of bradykinin-mediated conditions and insights from their AAE-C1INH research, where no approved therapies currently exist.

9 months ago

#PHVS Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

www.stocktitan.net/news/PHVS/pharvaris-pres...

0 0 0 0

Pharvaris Schedules Key Shareholder Meeting: What HAE Treatment Investors Should Know Biotech leader Pharvaris announces crucial shareholder meeting details for HAE treatment development updates. Registration required. Get meeting access details.

9 months ago

#PHVS Pharvaris Announces Annual Meeting of Shareholders

www.stocktitan.net/news/PHVS/pharvaris-anno...

0 0 0 0

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema Pharvaris (PHVS) presented promising data for deucrictibant in treating bradykinin-mediated angioedema at the 14th C1-Inhibitor Deficiency Workshop. The drug showed strong efficacy in both prophylactic and on-demand treatment settings. In prophylaxis, long-term data revealed sustained attack rate reduction for over 18 months, with maintained quality of life improvements. The new extended-release (XR) formulation demonstrated 24-hour therapeutic coverage supporting once-daily dosing. For on-demand treatment, 95-100% of attacks showed durable response without symptom reoccurrence after a single dose, with median symptom relief onset of 1.1 hours. Notably, deucrictibant effectively treated upper airway attacks with 92.9% requiring only one dose. The company also validated a novel biomarker assay for bradykinin-mediated angioedema, potentially expanding treatment opportunities.

9 months ago

#PHVS Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

www.stocktitan.net/news/PHVS/pharvaris-pres...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with bearish moving average convergence divergence crossovers, Tue May 13th - #ZTEK #VTYX #TALK #SATL #RLAY #PHVS #OTLY #LWAY #KPTI #INZY #IIIV #HITI #GAIA #ERAS #DOYU #AUPH #UVV #LTC #GRDN #CGAU - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update Pharvaris (PHVS) reported Q1 2025 financial results and provided updates on its development pipeline. The company is advancing deucrictibant, an oral bradykinin B2 receptor antagonist, through two pivotal Phase 3 studies: CHAPTER-3 for HAE attack prophylaxis and RAPIDe-3 for on-demand treatment. The FDA granted TQT study waivers for both deucrictibant formulations. Financial highlights include: cash position of €236M (down from €281M in Q4 2024), R&D expenses of €30.9M (up from €18.5M YoY), and a net loss of €46.3M (€0.85 per share). The company expects topline data from CHAPTER-3 in 2H2026 and will host an R&D call on June 4 to discuss expansion plans beyond HAE type 1/2.

10 months ago

#PHVS Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PHVS/pharvaris-repo...

0 0 0 0

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Pharvaris (PHVS) has achieved target enrollment in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for HAE attack treatment, while enrollment continues in CHAPTER-3 for HAE attack prophylaxis with topline data expected in 2H2026.The company received European orphan medicinal product designation for deucrictibant in bradykinin-mediated angioedema treatment. Recent clinical data presentations showed promising results in long-term prophylaxis and rapid treatment of HAE attacks, including upper-airway attacks.Financial highlights for FY2024:Cash position: €281 million (down from €391 million in 2023)R&D expenses: €98.6 million (up from €65.6 million in 2023)G&A expenses: €47.1 million (up from €31.3 million in 2023)Net loss: €134 million or €2.48 per share (compared to €100.9 million or €2.63 per share in 2023)

11 months ago

#PHVS Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/PHVS/pharvaris-repo...

0 0 0 0

Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status European Commission grants orphan designation to Pharvaris' Phase 3 drug deucrictibant, expanding treatment potential for bradykinin-mediated angioedema. Full analysis inside.

11 months ago

#PHVS Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

www.stocktitan.net/news/PHVS/pharvaris-anno...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #PHVS ) (PHVS) Technical Data

0 0 0 0

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress Pharvaris (PHVS) presented long-term clinical data for deucrictibant in treating hereditary angioedema (HAE) at the 2025 AAAAI/WAO Joint Congress. Key findings from the CHAPTER-1 OLE study showed sustained protection from HAE attacks over 1.5 years, with the median proportion of days with symptoms reduced to zero. All participants reaching week 62 reported improved health-related quality of life.In the RAPIDe-2 extension study, data from seven upper airway attacks showed a median time of 0.9 hours to symptom relief, consistent with results from 328 non-airway attacks. 85.7% of upper airway attacks were effectively treated with a single dose. The maximum exposure to deucrictibant was 20.8 months in the OLE study and 23.7 months overall, with no safety signals observed in both extension studies.

1 year ago

#PHVS Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

www.stocktitan.net/news/PHVS/pharvaris-pres...

0 0 0 0

Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment Pharvaris progresses dual Phase 3 trials for deucrictibant in HAE, plans AAE clinical study for 2025. Strong cash position extends runway to Q3 2026 as company preps for commercialization.

1 year ago

#PHVS Pharvaris Outlines 2025 Strategic Priorities

www.stocktitan.net/news/PHVS/pharvaris-outl...

0 0 0 0

1 year ago

#PHVS Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

www.stocktitan.net/news/PHVS/pharvaris-repo...

0 0 0 0

1 year ago

Just In: ( NASDAQ: #PHVS ) Trend Tracker for (PHVS)

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #PHVS ) Pharvaris Presents Data at the Bradykinin Symposium 2024

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #PHVS ) Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

#StockMarket #News

1 0 0 0